Phio Pharmaceuticals Corp (PHIO) — Titan Protect Analysis

PHIO

Phio Pharmaceuticals Corp

Healthcare · ·

$1.06

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$13M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.28

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-76.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$14.00

+1221% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RX

https://phiopharma.com

Country: United States Employees: 6 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.221

Positive but modest risk-adjusted returns

Kelly Fraction

0.0069

Marginal edge — very small allocation suggested

Calmar Ratio

-0.667

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-58.3%

Historical annualised return based on price data

Max Drawdown

-87.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$4.19

75% below the year high

52W Low

$0.81

30% above the year low

Avg Volume

221,804

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.38

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-7,254,875

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-10,932,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$14.00

Target Median

$14.00

Target Low

$14.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go